Phase II study of Chemotherapy for Advanced or Recurrent Thymoma

Phase II study of Chemotherapy for Advanced or Recurrent Thymoma - Chemotherapy for Advanced Thymoma

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000350

Enrollment

Registered

2006-04-01

Start date

2006-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thymoma (excluding thymic carcinoma)

Interventions

Carboplatin AUC5-6, day 1 Paclitaxel 180-210mg/m2 day 1 or 60-70mg/m2 weekly x3

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Thymoma, Masaoka Clinical Stage III or IV or recurrent thymoma. Performance Status 0-2. Measurable tumor (on CT, MRI or Chest X-ray). Pathological diagnosis of thymoma (excluding thymic cancer)(preferably with WHO classification). White blood cell count 4000/mm3 or more. Hemoblobin 9.0mg/dl or more. Serum AST, ALT not exceeding 100IU/L. Serum creatinin less than 1.2mg/dl. Total bilirubin 1.5mg/dl or less. Patient signs the written informed conscent.

Exclusion criteria

Exclusion criteria: Patients with malignancies other than thymoma (those with CR can be included). Patients who has been treated with steroid pulse therapy within one month of the registration. Patients on oral steroid at a dose of more than 26mg every other day or 13mg everyday. Pregnant women.

Design outcomes

Primary

Measure	Time frame
Response rate	—

Secondary

Measure	Time frame
Overall response Adverse effects	—

Countries

Japan

Contacts

Public ContactYoshitaka Fujii

Nagoya City University Medical School Second Department of Surgery

052-853-8231

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026